Allogeneic Bone Marrow-Derived Mscs
Hemophilia
Cairo UniversityCell therapyPhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
16 Active assets in the Hemophilia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ribavirin Kenneth Sherman | Phase 4 | BB |
Pegylated Interferon Alpha2A Baqiyatallah Medical Sciences University | Phase 4 | BB |
Eptacog Alfa Laboratoire français de Fractionnement et de Biotechnologies | Phase 3 | BB |
Fitusiran Sanofi | Phase 3 | BB |
Pcc Institute of Hematology & Blood Diseases Hospital, China | Phase 4 | B |
View all 33 →
Same molecule, other indications
Allogeneic Bone Marrow-Derived Mscs is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →